Venker Eric's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Sep 23, 2025
- Accession no.
- 0001140361-25-035890
- Filed
- Sep 23, 2025
- Trade date
- Sep 19-23, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $25.5M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venker EricCIK 0001801917 | Officer (President & Immunovant CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | Common Shares | MOption exerciseAcquired | +1,000,000 | $3.85 | +$3,850,000 | 2,653,585 | Direct | |
| Sep 19, 2025 | Common Shares | SSaleDisposed | −683,818 | $14.95F1 | −$10,223,079.1 | 1,969,767 | Direct | |
| Sep 22, 2025 | Common Shares | MOption exerciseAcquired | +462,374 | $3.85 | +$1,780,139.9 | 2,432,141 | Direct | |
| Sep 22, 2025 | Common Shares | MOption exerciseAcquired | +100,000 | $3.85 | +$385,000 | 2,532,141 | Direct | |
| Sep 22, 2025 | Common Shares | SSaleDisposed | −316,182 | $14.99F1 | −$4,739,568.18 | 2,215,959 | Direct | |
| Sep 22, 2025 | Common Shares | SSaleDisposed | −100,000 | $15.01F2 | −$1,501,000 | 2,115,959 | Direct | |
| Sep 23, 2025 | Common Shares | SSaleDisposed | −611,000 | $14.83F1 | −$9,061,130 | 1,504,959 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | Common Stock | MOption exerciseDisposed | −1,000,000 | $0.00 | $0 | 7,038,897 | Direct | |
| Sep 22, 2025 | Common Stock | MOption exerciseDisposed | −462,374 | $0.00 | $0 | 6,576,523 | Direct | |
| Sep 22, 2025 | Common Stock | MOption exerciseDisposed | −100,000 | $0.00 | $0 | 6,476,523 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Referenced by the price of 3 transactions in Table I.
- F2
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.
Referenced by the price of 1 transaction in Table I.